

Sotrovimab (Xevudy®) prescription for non-hospitalised patients with COVID-19 v3

Write in CAPITAL LETTERS or use addressograph

Surname: _____

First names: _____

Health and Care No: _____

DOB: _____

Allergies / Medicine Sensitivities
No known allergies <input type="checkbox"/> (please tick) or
Medicines (generic) / allergen (type of reaction)

Weight _____

Inclusion Criteria (all must apply)	Indicate Y/N
SARS-CoV-2 infection is confirmed by polymerase chain reaction (PCR) or lateral flow testing (registered via gov.uk or NHS 119)	
Symptomatic with Covid-19 and showing no signs of clinical recovery	
Patient is a member of a 'highest' risk group (as detailed in the Department of Health and Social Care commissioned Independent Advisory Group Report)	
Nirmatrelvir/ritonavir (Paxlovid®) is contraindicated or not suitable	
Treatment is commenced within FIVE days of symptom onset	
Off-label treatment may be commenced on days 6 or 7 post symptom onset if deemed clinically appropriate by the prescriber (see below)	
Exclusion Criteria (Patients are not eligible if they meet any of the following)	Indicated Y/N
Requirement for hospitalisation for COVID-19	
New supplemental oxygen requirement specifically for the management of COVID-19 symptoms	
Known hypersensitivity reaction to the active substances or to any of the excipients of the product listed in the Summary of Product Characteristics (SmPC)	
Aged under 12 years	
Aged 12 to 17 AND weight under 40kg	
<p>NIECR medications have been reviewed (please tick box and sign) <input type="checkbox"/> Signature: _____</p> <p>Sotrovimab (Xevudy®) 500mg concentrate for solution for infusion – Summary of Product Characteristics (SmPC) – (emc) https://www.medicines.org.uk/emc/product/13097</p> <p>Renal impairment: no dose adjustment is required in patients with renal impairment. Limited data in severe renal impairment – clinical decision</p> <p>Hepatic impairment: no dose adjustment is required in patients with hepatic impairment. No data in severe hepatic impairment – clinical decision</p> <p>Pregnancy and breastfeeding: No data for use in pregnant women or breastfeeding. The SmPC for Sotrovimab states that it may be used during pregnancy where the expected benefit to the mother justifies the risk to the foetus. Decisions on whether to breastfeed during treatment or to abstain from sotrovimab therapy should take into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p> <p>Weight: No data for use in adults weighing <40kg – clinical decision</p> <p>Off-label treatment may be commenced on days 6 or 7 post symptom onset if deemed clinically appropriate by the prescriber. This is not referenced in COVID-19 rapid guideline: Managing COVID-19 published 23 March 2021 updated 22/06/2023 Accessed 19/07/2023 but is referenced in the Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date:28th November 2022. If prescribing on day 6-7 post symptom onset patients should be advised that this is “off-label”.</p>	

SHSCT Pharmacy Department Version 4.0

References: COVID-19 rapid guideline: Managing COVID-19 published 23 March 2021 updated 22/06/2023 Accessed 19/07/2023 Available at: [Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE](#)

Electronic Medicines Compendium. SmPC Sotrovimab. Accessed 24/07/2023. Available at: [Xevudy 500 mg concentrate for solution for infusion - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)

Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date:28th November 2022

Sotrovimab (Xevudy®) prescription for non-hospitalised patients with COVID-19 v3

DRUG	DOSE	Fluid	Time	DAY	Route	Additional Info
Sotrovimab (Xevudy®)	500mg	100ml 0.9% sodium chloride	30 minutes	1	IV	Administer with a 0.2 micron in-line filter

Prescriber's Signature: _____	Prescriber's Name (Print): _____	Date: _____
GMC No _____	Grade: _____	Contact No: _____

Pharmacy Section

Send original prescription with supply of Sotrovimab to allow administration to occur, photocopy to be kept in Pharmacy (Green folder behind bench ACPTs final check at). Supply x1 packs of Sotrovimab 500mg and 0.2 micron in-line filter and charge to CAH COVID ISSUES GENERAL.

Batch Number: _____				Expiry Date: _____					
CC		LAB		DISP		FC		Date	

Administration information:

- A fluid balance chart must be completed to allow administration to occur
- Sotrovimab (Xevudy®) should not be infused concomitantly in the same IV line with other medicines
- Sotrovimab must be diluted prior to administration.
- Once diluted, attach an infusion set to the infusion bag using standard bore tubing. The intravenous dosing solution is recommended to be administered with a 0.2 µm in-line filter.
- Treatment must not be administered as an intravenous push or bolus.
- SPS recommends that 8ml Sotrovimab (Xevudy®) solution is added to the bag of sodium chloride 0.9% without removing an aliquot from the bag. [Handling and preparation of sotrovimab – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](#)
- All patients must be observed post infusion for acute infusion-related reactions/hypersensitivity reactions as per local policy – refer to the Summary of Product Characteristics (SmPC) and Interim Clinical Commissioning Policy for further information
- Report any suspected adverse reactions via www.mhra.gov.uk/yellowcard

Sotrovimab (Xevudy®)

Administration and Observation Chart

Patient addressograph	<p>Sotrovimab (Xevudy®) will be prescribed on the kardex / ICCA and on the fluid balance chart. The nurse administrator and checker to sign off both.</p> <p>Ensure that the patient has been advised (if patient's condition permits) to report any adverse symptoms e.g. shivering, shortness of breath, itch, rash or pain.</p>
-----------------------	---

FIRST INFUSION		Date infusion commenced:				Administration: (please sign and print name)
		Time infusion commenced:				1. 2.
Time	Interval	Temp	Pulse	BP	Resp	Comments
	Baseline					
	15 mins					
	End of infusion (30mins)					
	30 mins after infusion					
	60 mins after infusion					
Time infusion ended:				Was total unit volume infused?		
Total volume transfused				If no please specify		

SHSCT Pharmacy Department Version 4.0

References: COVID-19 rapid guideline: Managing COVID-19 published 23 March 2021 updated 22/06/2023 Accessed 19/07/2023 Available at: [Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE](#)

Electronic Medicines Compendium. SmPC Sotrovimab. Accessed 24/07/2023. Available at: [Xevudy 500 mg concentrate for solution for infusion - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)

Interim Clinical Commissioning Policy: Treatment for non-hospitalised patients with COVID-19. Publication date: 28th November 2022